Two small regions deep in the brain may begin losing tissue years before a person notices any memory trouble from Alzheimer's disease, according to Johns Hopkins University researchers. In a study announced on 14 November 2026, the team reported that the entorhinal cortex and the amygdala shrink earlier than the hippocampus, the structure doctors usually look at when assessing the disease.

The researchers suggest that tracking tissue loss in these two areas together could become an early warning sign, possibly as much as a decade before symptoms appear. They also stress that the work is not yet a diagnostic test.

What the team studied

The findings were published in the journal NeuroImage: Reports and are being presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience, the university said.

The group analysed hundreds of MRI and PET scans drawn from two long-running research cohorts: the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study, known as BIOCARD. The scans were collected over time from people who had no symptoms, people with cognitive impairment, and people who later died from the disease.

Using these repeated scans, the researchers measured atrophy, or loss of volume, in the entorhinal cortex, the amygdala and the hippocampus, and compared how quickly each region changed.

Key findings

  • In both cohorts, the entorhinal cortex and the amygdala showed greater relative shrinkage than the hippocampus in the early phase of the disease.
  • The areas of grey-matter loss lined up with changes linked to tau, a protein associated with Alzheimer's, which the team examined with PET imaging and digital pathology.
  • The authors propose measuring atrophy in the two regions together as a possible early biomarker.

"We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms," senior author Michael Miller said in the Johns Hopkins release. "It's at least a 5-to-10-year play where your brain is changing."

Why earlier detection matters

Miller said in the release that the hope is to treat neurodegenerative changes "at the 2, 3 or 4-year point rather than after 15 years when the changes are manifesting in memory symptoms."

Co-author Marilyn Albert, director of the Johns Hopkins Alzheimer's Disease Research Center, said the goal is "to be able to treat individuals before the symptoms of Alzheimer's disease develop."

Neuropathologist Meaghan Morris, another co-author, said that as biomarkers and treatments become more widely available, knowing who is going to experience cognitive decline "is going to be really important." She added that the approach "could really play into better risk stratification."

The researchers raised the possibility that people with a family history of the disease or other concerns might one day be scanned in their 30s and 40s.

Limits and next steps

The team cautioned that more work is needed before these measurements can be used to diagnose patients. The study identifies a potential early marker; it does not provide a clinical test that predicts Alzheimer's years ahead.

Miller said the group's next goal is to map the "molecular neighborhoods" associated with the tau changes highlighted by the scans. "Once we know more about the molecular neighborhoods, we can develop therapies," he said.

The work was funded by the US National Institutes of Health, the US National Science Foundation and the Kavli Neuroscience Discovery Institute, according to the release.

PS